Raphael Pharma Reports $1K Cash, Confirms Going Concern, Needs $2M Funding

summarizeSummary

Raphael Pharmaceutical reported a critically low cash balance of $1,000 and reiterated its going concern warning, despite reducing quarterly losses and cash burn, indicating an urgent need for significant financing.

check_boxKey Events

• Critically Low Cash Reserves

  The company reported only $1,000 in cash and cash equivalents as of March 31, 2026, a sharp decline from $45,000 at year-end 2025.

• Going Concern Warning Reiterated

  Management and auditors continue to express substantial doubt about the company's ability to continue operations, with existing cash projected to last only through the third quarter of 2026.

• Significant Funding Gap

  Raphael Pharmaceutical anticipates needing approximately $2 million for research and development and capital expenditures over the next 12 months.

• Reduced Operating Losses

  Net loss decreased by 47% to $229,000, and net cash used in operating activities decreased by 79% to $44,000 for Q1 2026 compared to the same period in 2025, indicating some operational efficiency improvements.

auto_awesomeAnalysis

This quarterly report confirms Raphael Pharmaceutical's critically low cash position of just $1,000, reiterating the substantial doubt about its ability to continue as a going concern. While the company significantly reduced its net loss and cash burn compared to the prior year, the current cash runway extends only through Q3 2026, highlighting an urgent need for approximately $2 million in additional financing. The dire cash balance and short runway present an immediate and severe challenge to the company's operations and future viability.